Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Immunogenicity of a 5-dose pneumococcal vaccination schedule following allogeneic hematopoietic stem cell transplantation
American Journal of Hematology, Volume 97, No. 5, Year 2022
Notification
URL copied to clipboard!
Description
The optimal schedule of pneumococcal vaccination after allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains controversial. The objective of this study was to investigate the immunogenicity of a 5-dose pneumococcal vaccination schedule in adult allo-HSCT recipients with and without immunosuppressive therapy. In this prospective cohort study, allo-HSCT recipients received four doses of the 13-valent pneumococcal conjugate vaccine (PCV13) and one dose of the 23-valent pneumococcal polysaccharide vaccine (PPSV23) starting 4–6 months after allo-HSCT. PCV13 was administered at T0, T1, T2, and T8 (T = months from enrollment) and PPSV23 at T10. Serum was collected at T0, T4, T8, T10, and T12, and IgG levels were measured for all 24 vaccine serotypes by immunoassay. The primary outcome was overall seroprotection at T12 defined as an IgG concentration ≥1.3 μg/ml for 17/24 vaccine serotypes in allo-HCST recipients with and without immunosuppressive therapy at baseline. Secondary outcomes were serotype-specific seroprotection and dynamics of IgG levels. We included 89 allo-HSCT recipients in the final analysis. Overall seroprotection was 47% (15/32) for patients without immunosuppressive therapy at baseline versus 24% (11/46) for patients with immunosuppressive therapy (p =.03). Seroprotection was higher for PCV13 serotypes (78% and 54% respectively; p =.03) and lower for PPSV23-unique serotypes (28% and 13% respectively; p =.1). IgG concentrations increased significantly over time for all 24 serotypes. Concluding, although immunogenicity of PCV13 serotypes was reasonable, the poor response to PPSV23 serotypes resulted in an insufficient overall response to pneumococcal vaccination for allo-HSCT recipients. Research into vaccination strategies with higher-valent T-cell-dependent pneumococcal vaccines is needed. © 2022 The Authors. American Journal of Hematology published by Wiley Periodicals LLC.
Authors & Co-Authors
Meijer, Ellen
Netherlands, Amsterdam
Cancer Center Amsterdam
Tanck, Michael W.T.
Netherlands, Amsterdam
Universiteit Van Amsterdam
Hazenberg, Mette D.
Netherlands, Amsterdam
Cancer Center Amsterdam
Netherlands, Amsterdam
Sanquin Research
de Bree, Godelieve J.
Netherlands, Amsterdam
Amsterdam Institute for Infection and Immunity
Nur, Erfan
Netherlands, Amsterdam
Cancer Center Amsterdam
Netherlands, Amsterdam
Sanquin Research
Grobusch, Martín Peter
Netherlands, Amsterdam
Amsterdam Institute for Infection and Immunity
Goorhuis, Abram
Netherlands, Amsterdam
Amsterdam Institute for Infection and Immunity
Statistics
Citations: 7
Authors: 7
Affiliations: 5
Identifiers
Doi:
10.1002/ajh.26493
ISSN:
03618609
Study Design
Cohort Study
Study Approach
Quantitative